The site on the HIV-1 gp120 glycoprotein that binds the CD4 receptor is recognized by broadly reactive antibodies, several of which neutralize over 90% of HIV-1 strains. To understand how antibodies achieve such neutralization, we isolated CD4-binding-site (CD4bs) antibodies and analyzed 16 co-crystal structures -8 determined here-of CD4bs antibodies from 14 donors. The 16 antibodies segregated by recognition mode and developmental ontogeny into two types: CDR H3-dominated and V H -gene-restricted. Both could achieve greater than 80% neutralization breadth, and both could develop in the same donor. Although paratope chemistries differed, all 16 gp120-CD4bs antibody complexes showed geometric similarity, with antibody-neutralization breadth correlating with antibody-angle of approach relative to the most effective antibody of each type. The repertoire for effective recognition of the CD4 supersite thus comprises antibodies with distinct paratopes arrayed about two optimal geometric orientations, one achieved by CDR H3 ontogenies and the other achieved by V H -gene-restricted ontogenies.
In Brief
A population-level analysis of antibodies that recognize the CD4-binding site on the HIV-1 gp120 glycoprotein, the target of some of the most potent and broadly neutralizing antibodies, defines structural geometries, binding chemistries, and developmental pathways of antibody recognition, providing a catalog from which to choose optimal templates for vaccine design. 4YDJ  4YDK  4YDL  4YDI  4RWY  4RX4  4YFL  4YE4  KP860914  KP860918 INTRODUCTION Successful vaccines often recapitulate effective immune responses induced by natural infection. In the case of HIV-1, antibodies capable of neutralizing about half of circulating strains develop after years of chronic infection in about half of examined donors (Hraber et al., 2014) . Isolation and mapping of these neutralizing responses show that they target most of the exposed surface of the prefusion mature closed state of the HIV-1 Env spike Lyumkis et al., 2013; Pancera et al., 2014) . Despite this broad targeting, highly effective antibodies develop preferentially against just a few sites of vulnerability on HIV-1 Env. These ''supersites'' of vulnerability have been the focus of intense vaccine interest. Each supersite appears to be targeted by broadly neutralizing antibodies that arise in many infected individuals, by broadly neutralizing antibodies with diverse modes of recognition, and by broadly neutralizing antibodies with diverse B cell ontogenies (reviewed in Kwong and Mascola, 2012; West et al., 2014) . Thus the human immune system has multiple avenues by which to generate effective antibodies against these supersites, thereby providing a rationale for their suitability as focuses of vaccine efforts.
Accession Numbers
One of these supersites, the CD4 supersite, is the site of binding for the CD4 receptor on the HIV-1 gp120 envelope glycoprotein. All primate immunodeficiency viruses recognize CD4 as the primary attachment molecule on the cell surface (Hoxie et al., 1988; McClure et al., 1987) , and therefore, despite the great genomic and hence antigenic variation between HIV-1 strains, the CD4bs is relatively well conserved (Kwong et al., 1998; Lyumkis et al., 2013; Pancera et al., 2014) . Potent broadly neutralizing CD4-binding-site (CD4bs) antibodies are frequently observed during the chronic stage of infection (Binley et al., 2008; Li et al., 2007; Lynch et al., 2012; Pancera et al., 2014; Walker et al., 2010) , and numerous CD4bs antibodies have been identified (Burton et al., 1994; Corti et al., 2010; Georgiev et al., 2013; Liao et al., 2013; Scheid et al., 2011; Wu et al., 2010; Wu et al., 2011; Zhu et al., 2013) . Analysis of co-crystal structures of core gp120s with three of these CD4bs antibodies, b12, VRC01, and CH103, reveals distinct modes of structural interaction (Liao et al., 2013; Zhou et al., 2007 Zhou et al., , 2010 , all of which involve substantial interactions with the conformationally invariant gp120 outer domain.
Additional antibody co-crystal structures , however, showed that CD4bs antibodies from different donors could have similar modes of recognition and similar B cell ontogenies, suggesting that the repertoire of effective CD4bs antibodies might be limited. Because an understanding of the variation in binding characteristics of antibodies specific for a supersite is expected to provide insight regarding how such antibodies might be induced in the general population, we sought to study antibody recognition of the CD4 supersite in multiple donors. We used antigen-specific probes to isolate CD4bs antibodies from diverse germline V H genes. We determined cocrystal structures with the HIV-1-Env gp120 glycoprotein for these and for previously identified antibodies HJ16, 1B2530, 8ANC131, and 8ANC134 (Corti et al., 2010; Scheid et al., 2011) and characterized B cell ontogenies and paratope chemistries. The repeated observation of similar CD4bs antibodies in 14 donors provided a means to delineate the repertoire for effective recognition of the CD4 supersite. The results define structural geometries, recognized surfaces, paratope chemistries, and developmental pathways of CD4bs recognition, thereby providing a population-level understanding of antibodies targeting the CD4 supersite as well as a catalog from which to choose optimal templates for vaccine re-elicitation.
RESULTS

Identification of CD4bs Antibodies with Diverse Germline Origin Genes
To provide a more comprehensive view for how human antibodies recognize the CD4 supersite, we sought to identify CD4bs antibodies from additional donors. In particular, we were interested in determining whether highly effective neutralizing antibodies could originate from heavy-chain germline genes other than VH1-2 or VH1-46, the germline origin genes from which virtually all previously identified effective CD4bs antibodies derive. Sera from donors 44, C38, and Z258 showed a substantial reduction in neutralization when adsorbed with the RSC3 probe, a modified core gp120 designed to retain only the outer domain contact of CD4 . With donor 44, we used RSC3 sorting and PCR recovery of individual B cell antibody variable regions (Scheid et al., 2009; Tiller et al., 2008) to isolate an antibody named ''44-VRC13.01'' (named for ''donor-antibody lineage.clone''; after the first mention of the complete antibody name, we refer to each antibody by its lineage name) ( Figure S1 ). VRC13 utilized a V H gene derived from VH1-69 ( Figure S1 ) and neutralized 82% of circulating HIV-1 isolates (Table S1) . From donor C38, we isolated two antibodies: C38-VRC16.01 and C38-VRC18.02 ( Figure S1 ). VRC16 utilized a V H gene derived from VH3-23 and neutralized 58% of HIV-1 strains; VRC18 utilized a V H gene derived from VH1-2, was highly similar to an NGS-derived antibody from donor C38 , and neutralized 67% of HIV-1 strains (Table S1) . From donor Z258, we isolated antibody Z258-VRC27.01. This antibody utilized a V H gene derived from VH1-2 and neutralized 78% of HIV-1 strains ( Figure S1 and Table S1 ). Altogether, we identified four potent and broadly neutralizing CD4bs antibodies, two of which were derived from V H genes not previously observed in effective CD4bs antibodies.
Two Types of CD4bs Antibody Recognition
To define the structural modes of antibody recognition, we produced antigen-binding fragments (Fab) and crystallized these in complex with extended core versions of the HIV-1 gp120 envelope glycoprotein (Kwon et al., 2012) . In addition to the four newly identified antibodies, we determined structures for antibodies from three donors with broadly neutralizing antibodies that had not been characterized structurally: the VH3-30-derived antibody HJ16 from donor 242315 (Corti et al., 2010; North et al., 2011) as well as the VH1-46-derived antibodies 1B2530 from donor RU1 and 8ANC131 and 8ANC134 from donor RU8 . These eight new structures ( Figure 1 and Table S2 ) from seven distinct B cell lineages nearly double the number of lineages with structurally defined CD4bs antibody-gp120 complex structures (Table S3) .
Structures of HIV-1 gp120 with antibodies from VH1-2 germline (VRC18 and VRC27) or from VH1-46 germline (1B2530, 8ANC131, and 8ANC134) revealed antibody interfaces dominated by the heavy-chain second complementarity determining region (CDR H2) (Figure 2A ). This ''type,'' or mode, of recognition for both VH1-2-and VH1-46-derived antibodies was very similar, although the binding angles of VH1-46-derived antibodies relative to that of CD4 for 8ANC131 and 8ANC134 were on the outskirts of the strict confines of the VH1-2-derived antibodies ( Figure 2B ). By contrast, structures of antibodies from germlines other than VH1-2 or VH1-46 (VRC13, VRC16, and HJ16) revealed antibody interfaces dominated by CDR H3, which in each case contributed $75% of the heavy-chain interface ( Figure 2A and Table S4 ). Overall, structural analysis revealed broadly neutralizing CD4bs antibodies to fall into two distinct types-CDR H3-dominated or V H -gene-restricted-and also provided characteristic features for each type of antibody recognition (Table S3 ).
Conserved Geometry of CD4bs Recognition
Despite type-specific features, gp120-binding orientations of the eight newly defined antibodies were similar to each other and to previously determined structures from eight donors Liao et al., 2013; Wu et al., 2011; Zhou et al., 2010 Zhou et al., , 2013 (Figure 2C ). For the 15 unique broadly neutralizing CD4bs lineages, the heavy chain comprised the major interactive component (77% ± 10% of the interface). For all 15, the light chain was oriented toward the viral membrane ( Figures 2D and  S2 ). Antibodies targeting the CD4bs were constrained geometrically both in latitudinal accessibility, which defines freedom between viral and host cell membranes, and in longitudinal accessibility, which defines freedom within the plane of the membrane (relative to the viral spike, the latitudinal axis is perpendicular to the trimer axis, and the longitudinal axis is parallel to this axis).
While the V H -gene-restricted antibodies clustered with similar latitudinal angles, the four antibodies of the CDR H3-dominated type each showed latitudes, which were similar to that of CD4 ( Figure 2C , left and upper-right panels). The constraint in longitude was also pronounced ( Figure 2C , middle and lower-right panels), with most longitudes within 20
. Overall, the restriction in binding orientation appeared to be substantially greater than observed with antibodies against model antigens such as henegg white lysozyme (Braden et al., 1994; Desmyter et al., 1996; Padlan et al., 1989) or against other supersites of HIV-1 vulnerability, such as the membrane-proximal external region on gp41, where antibodies 2F5, 4E10, and 10E8 have divergent binding orientations (Cardoso et al., 2005; Huang et al., 2012; Ofek et al., 2004) , or the glycan-V3 supersite on gp120, where longitudinal approach angles ranged from 15 to 95 degrees among four representative antibodies (PGT122, PGT128, PGT135, and 2G12) (Calarese et al., 2003; Julien et al., 2013; Kong et al., 2013; Pejchal et al., 2011) (Figure S3 ).
To gain an overall understanding of the relationship between breadth of neutralization and binding orientation, we compared the orientation of CD4bs antibodies relative to the most effective CD4bs antibodies thus far developed, modified somatic variants of the VRC01 lineage such as antibody 45-46m2 or antibody VRC07-523 Diskin et al., 2011; Rudicell et al., 2014) (PDB: 4JKP and 4OLW) . For this analysis, we added three CDR H3-dominated recognizers-b12, b13, and F105-to the current panel of 16 antibodies (Chen et al., 2009; Zhou et al., 2007) . Strong correlation between antibody orientation and neutralization breadth was observed (p < 0.0001, R 2 = 0.64), with the VH1-2-derived antibodies that were the most similar in angular orientation to antibodies 45-46m2 and VRC07-523 also showing the highest breadth, and these were followed by VH1-46 antibodies and CDR H3-dominated recognizers (Figure 3, top) . Separate correlations of CDR H3-dominated and V Hgene-restricted CD4bs relative to the most effective antibody of each type also showed strong correlation ( Figure 3 , middle and bottom panels). Altogether, effective CD4bs antibodies shared highly similar orientations, both in terms of overall antibody angle of approach and in terms of heavy-light chain orientation relative to the spike (Figures 2 and 3 ). However, the two different types of antibodies-CDR H3-dominated and V H -gene-restricted-correlated better with breadth when Complex structures are shown from a common alignment with gp120 (gray surface representation), with the light chains shown in blue and the heavy chains shown in red, green, and brown for CDR H3-dominated recognizers, VH1-2-derived heavy chains, and VH1-46-derived heavy chains, respectively. See also Figure S1 and Tables S1 and S2. Table S3 . and S4.
treated as separate groups, with CD4bs antibodies clustering around two optimal structural modes of recognition, which were embodied by the most effective antibodies of each type (Figures 2 and 3) .
B Cell Ontogenies
In addition to type, which reflects structural mode of recognition, CD4bs antibodies can be delineated by class, which further categorizes antibodies by their B cell ontogeny (Kwong and Mascola, 2012; West et al., 2014) . B cell ontogeny accounts for genetic similarities in developmental pathways and also includes maturation processes such as affinity for antigens that initiate B cell maturation and degree of affinity maturation required for neutralization breadth. Thus, a single type of recognition may be achieved by different B cell ontogenies, resulting in different classes of antibodies (Table S3) . To define the class of each of the CD4bs antibodies, we studied their ontogenies. The ontogenies of VH1-2-derived CD4bs antibodies have been defined previously. As a group, they are unified by (1) very weak to undetectable binding to gp120 of germline V-gene revertants of heavy and light chain in which the CDR H3 or L3 are mature (gHgL) Klein et al., 2013; McGuire et al., 2013; Mouquet et al., 2010; Scheid et al., 2011; Zhou et al., 2010) , (2) similarities in heavy-chain evolution (Wu et al., 2011) , and (3) a specific light-chain sequence signature (West et al., 2012; Zhou et al., 2013) . These characteristics define the VRC01 class of neutralizing antibodies, named for the first member of this class, VRC01 ) from donor 45 (Wu et al., 2015) . Among the new antibodies described here, VRC18 and VRC27 are members of the VRC01 class.
When we analyzed the binding of gHgL revertants of the VH1-46-derived antibodies, 8ANC131 and 1B2530, to a panel of fulllength gp120s, no detectable binding was observed, (Figure 4A ), similar to the behavior observed for VH1-2-derived VRC01 class members Zhou et al., 2010) . Cross-donor phylogenetic analysis (Wu et al., 2011) indicated that the VH1-46 derived antibodies from donors RU1 and RU8 evolved with sufficient similarity to allow the identification of 8ANC131 sequences with 1B2530 sequence similarity and vice versa (Figure 4B and Table S5 ). We did not observe a specific heavy-or light-chain signature. Moreover, when we analyzed immunogens capable of binding the gHgL of VH1-2-derived antibodies , we found that the mature forms of antibodies 1B2530 and 8ANC131 bound well to these immunogens, but the gHgL of VH1-46-derived antibodies were unable to bind ( Figure S4 ). Thus, while the VH1-46-derived antibodies were similar to those from the VRC01 class, the preponderance of ontological features indicated VH1-46-derived antibodies to form a separate class, which we named the 8ANC131 class, after the most effective member of this class .
For the CDR H3-dominated antibodies, only the ontogeny of the CH103 antibody has been analyzed in detail previously (Liao et al., 2013) . None of the four CDR H3-dominated antibodies analyzed here utilized the same origin genes (V H , D, J H , V L/K , and J L/K ) except CH103 and VRC13, which shared the same J l gene; however, because the light-chain J region did not contribute substantially to recognition with either CH103 or VRC13, the J l usage was likely not critical to the ontogeny of these antibodies. We tested the recognition of gHgL versions of the four CDR H3-dominated antibodies: the gHgL of VRC13 and VRC16 showed weak and moderate binding to several gp120s, while gHgL of CH103 and HJ16 showed no detectable binding ( Figure 4A ). In terms of heavy-chain evolution, donor samples for B cell sequencing were available from donors 44 and C38, the sources of antibodies VRC13 and VRC16, respectively. Cross-donor analysis with heavy-chain sequences showed no similarities in evolution between VRC13 and VRC16 To determine a common reference frame for calculations of angular difference, antibody-gp120 structures were first aligned to a common reference frame based on core gp120; to determine angular difference relative to the most effective antibody, a second superposition was performed to align each antibody to the most effective antibody referent; rotation angles determined from this second superposition are shown.
or between these antibodies and any of the sequences from V H -gene-restricted donors ( Figure 4B ). Finally, we could not identify any sequence signatures in the paratopes of the CDR H3-dominated antibodies. In light of these data on gene origin, gHgL recognition, heavy-chain evolution, and sequence signature, we conclude that antibodies CH103, HJ16, VRC13, and VRC16 each have different B cell ontogenies and therefore represent separate antibody classes ( Figure 4C and Table S3 ).
Epitope Characteristics of CD4bs Antibodies
To define the HIV-1-Env surface recognized by highly effective antibodies from 14 donors, we analyzed their epitopes. (B) Similarities in heavy-chain maturation. Numbers in the table correspond to the number of heavy-chain sequences retrieved from heavy-chain transcripts determined by NGS of B cells from each donor; retrieval was accomplished by cross-donor phylogenetic analysis with the template antibody from the first column. Gray highlighted areas correspond to matching lineages and classes. The table diagonal represents matching antibodies and donors; when antibodies are found off the diagonal, this indicates similarity in heavy-chain maturation. (C) Class characteristics of effective CD4bs antibodies. See also Figure S4 and Table S5. Recognized surfaces overlapped considerably, although substantial variation was observed with antibodies encoding CDR H3-dominated recognition. For example, HJ16 recognized an epitope that extended toward the viral membrane and shared <50% overlap in recognized Env surface with VRC13. For the V H -gene-restricted antibodies, epitope surfaces revealed a characteristic discontinuity near the center of the epitope, a feature shared with CD4 ( Figures 5A and 5B ). This discontinuity was not observed for antibodies with CDR H3-dominated recognition, where the penetrating CDR H3 loops formed contiguous complementary molecular surfaces. To determine whether these differences in recognition could be detected functionally, we analyzed the neutralization fingerprints for all 16 CD4bs antibodies on a panel of 178 genetically diverse viruses (D) Potency of CD4-binding site antibodies mapped to the supersite. The worm representation of HIV-1 gp120 is colored by averaged antibody potency, with thickness representing average buried binding surface area of corresponding residues; notably, in addition to the outer domain contact on gp120 for CD4, neighboring regions in the inner domain and on strands b20/21 contribute to the supersite. See also Figure S5. ( Figure 5C ). While the neutralization profile of CD4bs antibodies segregated from antibodies targeting other Env sites, within the CD4bs cluster, the most divergent were the VH1-46-derived and CDR H3-dominated antibodies, with 1B2530 and HJ16 falling outside of the main CD4bs cluster. The remaining members of the CD4bs classes were interleaved. To provide a per residue understanding of the CD4 supersite, we combined recognized epitope with neutralization potency to construct a residue-level picture of the CD4 supersite ( Figures 5D and S5) . Overall, despite differences in structural mode of recognition and class, all of the CD4bs antibodies displayed general similarities in terms of recognized epitope and profile of viruses neutralized.
Paratope Characteristics of CD4bs Antibodies
To understand how these antibodies recognize the CD4 supersite, we analyzed their paratopes. First, we structurally aligned gp120 components from co-crystal structures and analyzed known hot spots of CD4 interaction (Ryu et al., 1990; Wang et al., 1990) (Figure 6 ) (for clarity, from this point forward, residues are displayed with a subscript defining the molecule). Within domain 1 of CD4, Phe43 CD4 makes contacts with the ''Phe43 cavity'' on gp120 and forms hydrophobic interactions with Glu370 gp120 , Ile371 gp120 , and Trp427 gp120 and backbone contacts with residues 425 gp120 and 473 gp120 ( Figure 6A and Table S6 ). Interestingly, a similar hydrophobic interaction was observed in some of the VH1-2-derived VRC01-class antibodies, including Trp54 VRC-PG20 , Phe54 12A21 , and Phe54 VRC27 . Despite this interaction being highly favorable Rudicell et al., 2014) , it was not preserved in other members of the VRC01 class. For example, with VRC01, residue 54 VRC01 is a glycine, and no hydrophobic residue substitutes for this interaction ( Figure 6A ). For the VH1-46-derived antibodies, no similar residue is found in 8ANC131, but for antibody 1B2530, Arg54 1B2530 engages the gp120 Phe43 cavity in a manner similar to VH1-2 antibody VRC23. Meanwhile, with the CDR H3-dominated antibodies, in VRC16, the phenyl ring of Tyr100E VRC16 is oriented almost identically to that of Phe43 CD4 , whereas in CH103, HJ16, and VRC13, no similar interactions are observed; indeed, HJ16 does not even interact with the Phe43 cavity ( Figure S6) . Thus, the specific chemical interactions at the Phe43 cavity of gp120 appeared to be highly variable.
In terms of the other highly favorable interaction within domain 1 of CD4, Arg59 CD4 forms electrostatic interactions with Asp368 gp120 ( Figure 6B ). With all of the V H -gene-restricted type antibodies, both from VH1-2 and VH1-46 origins, Arg71 heavy chain makes similar interactions. Notably, the combination of a CDR H2-dominated interface along with use of Arg71 heavy chain may explain the restricted V H gene usage of this antibody type. Many common V H genes encode Arg71 heavy chain , but this residue is often buried between CDR H2 and CDR H1 (North et al., 2011) . VH1-2 and VH1-46 seem to possess CDR H2 sequence features (such as Pro52A heavy chain ) that lead to a CDR H2 conformation that is compatible with gp120 binding and that exposes Arg71 heavy chain (see ''Germline Gene Usage of the VH Gene-Restricted Antibodies'' in Supplemental Information). In the CDR H3-dominated antibodies, both CH103 and VRC13 use Arg residues (Arg97 CH103 and Arg96 VRC13 ) to mimic the interactions of Arg59 CD4 , but antibody HJ16 has no equivalent interactions, and antibody VRC16 uses a His side chain to approximate this interaction ( Figure 6B) . Thus, the specific chemical interactions with Asp368 gp120 appeared to be mostly, though not entirely, conserved. Figure S6 and Table S6 .
To provide an overall understanding of the recognition surface, we analyzed paratope chemistry utilized in recognizing the CD4 supersite ( Figure 7 and Table S7 ). We observed substantial interclass differences, with CDR H3-dominated antibodies displaying especially varied binding surfaces and interactive chemistry. We also examined intra-class differences between different donors with antibodies derived from common V H genes ( Figure 7B ). Among members of the VRC01 class ( Figure 7B, left) , paratope chemistry and atom type (Petrey and Honig, 2000) were similar despite the paratope being altered by substantial somatic hypermutation. Notably, this hypermutation occurred in similar regions of the paratope, likely reflecting similarities in ontogeny and in requirements to achieve optimal recognition. Substantial diversity, however, was observed among antibodies of the 8ANC131 class from different donors ( Figure 7B, right) .
Thus, highly effective CD4bs antibodies, even those of the same B cell ontogeny, can develop distinct paratope chemistry.
These differences in paratope chemistry indicate that the immune system can find diverse solutions to the recognition of the same target epitope.
DISCUSSION
While antibodies of the human immune system can recognize epitopes in diverse ways, repeated observations in 14 donors of similar geometries of recognition and similar B cell ontogenies suggest the repertoire for broad neutralization to be relatively limited. One potential explanation for this limitation is that HIV-1 Env is so well protected from antibody recognition that the humoral immune system can develop effective recognition-even against the more prevalently recognized supersites of Env vulnerability-through only a few pathways.
It may be important to identify critical factors that constrain the development of effective recognition, and one way to do this is See also Figure S7 and Table S7. to analyze the recognition of multiple antibodies that target the same supersite at the population level. Elements of diversity between these antibodies would indicate factors that allow the immune system to develop multiple solutions; elements of similarity would indicate dominant constraining factors. In the case of the CD4 supersite, we observed the overall geometry of antibody recognition to be highly similar ( Figure 7A ); this suggested a dominant constraining factor for the elicitation of CD4bs antibodies to be paratope accessibility at the recessed CD4 supersite on functional viral spikes Pancera et al., 2014) .
The 14 donors analyzed here define our current understanding of the human antibody repertoire that can effectively recognize the CD4 supersite on HIV-1. While surrounded by glycan, the surface that binds CD4 is itself free of glycan (Kwong et al., 1998) ; indeed, it is the only epitope cluster on the HIV-1-Env spike that is both glycan free and not membrane proximal (Pancera et al., 2014) . The V H -gene-restricted classes that successfully target this site each appear in multiple donors and share evolutionary similarities, suggesting developmental pathways accessible to the general population. By contrast, the CDR H3-dominated classes each appear in a single donor and show no detectable evolutionary similarity or sequence signature, suggesting origins that are stochastic and therefore not shared between different individuals. Because the germline-reverted (gHgL) versions of the V H -gene-restricted and CDR H3-dominated antibodies showed different binding behaviors to gp120, we assessed their B cell activation properties to provide insight into early development. Calcium flux experiments indicated that B cell triggering could occur with gHgL versions of VRC13, but not VRC01 ( Figure S4 ), demonstrating differences in ontogeny whereby germline versions of some CDR H3-dominated antibodies could trigger B cell activation more efficiently than germline-reverted versions of antibodies from V H -generestricted classes. This was supported by the binding of the germline-reverted version of the CDR H3-dominated VRC13 and VRC16 (Figure 4A ), by the autologous-virus specific binding of the unmutated common ancestor of the CDR H3-dominated CH103 (Liao et al., 2013) , and by the lack of binding for germline-reverted versions of V H -gene-restricted antibodies (Figures  4 and S4) McGuire et al., 2013; Zhou et al., 2010) . Finally, the inability of germline-reverted VH1-46 antibodies to bind immunogens, which had been developed to recognize germline-reverted VH1-2 antibodies, indicated that different classes of V H -gene-restricted antibodies may require different immunogens. Together, the results suggest that distinct immunogens may be required to stimulate the development of the different types and classes of broadly neutralizing antibodies that recognize the CD4 supersite.
Overall, the CD4bs antibody analysis described here, the first comprehensive analysis of antibody recognition for a supersite of HIV-1 vulnerability, provides a framework linking structural mode of antibody recognition (type) with B cell ontogeny (class) and paratope chemistry in 14 donors (Table S3) . Serum from these donors displayed a range of potencies though with breadths generally in the upper range ( Figure S7 ). This population-level analysis provides insight into constraining factors (e.g., from similarities in elicited antibodies) as well as the ease by which the immune system can replicate a particular lineage pathway (e.g., from similarities in ontogeny). The results indicate that the repertoire for effective recognition of the CD4 supersite consists of antibodies with diverse paratopes that cluster around two solutions: one achieved by V H -gene-restricted ontogenies and the other achieved by CDR H3-dominated ontogenies. The V H -gene-restricted solution, embodied by antibodies 45-46m2 and VRC07-523 Rudicell et al., 2014) , uses the CDR H2 region to mimic the C 00 recognition of CD4 (Kwong et al., 1998) though with a different latitudinal orientation to accommodate the light chain . The CDR H3-dominated solution, embodied by antibody VRC13 isolated here, uses the CDR H3 region to recognize the CD4 supersite, with the same latitudinal angle as CD4. It will be interesting to see whether additional broadly neutralizing CD4bs antibodies will continue to cluster around these two solutions and whether other highly effective solutions to the problem of antibody recognition of the CD4 supersite can be found.
EXPERIMENTAL PROCEDURES
Human Specimens Donors 44, C38, and Z258 participated in NIAID protocols (Doria-Rose et al., 2009) at the National Institutes of Health, Bethesda, MD, USA. HIV infection was documented by HIV-1/2 immunoassay. The donors were chronically infected and had not initiated antiretroviral treatment at the time of sample collection. All human samples were collected with informed consent under clinical protocols approved by the appropriate institutional review board (IRB).
Isolation and Expression of Antibody 44-VRC13.01, C38-VRC16.01, C38-VRC18.02, and Z258-VRC27.01 Antigen-specific memory B cells from donors 44, C38, and Z258 were isolated with Avi-tagged RSC3 and DRSC3 and were single-cell sorted on a FACS Aria II as described previously Supplemental Experimental Procedures) Production and Purification of HIV-1 Env Protein and Antibodies HIV-1 gp120 proteins were produced in GNTIÀ/À cells and were purified as described previously . Human antibodies were expressed in HEK293F cells and were purified by protein A affinity chromatography. Antigen-binding fragments (Fab) of antibodies were prepared by overnight Lys-C digestion at 37 C with a IgG:Lys-C ratio of 4,000:1 (w/w) and sequential purification over protein A and size exclusion columns.
Neutralization Assays
Single round of replication Env-pseudoviruses were prepared, titered, and used to infect TZM-bl target cells as described previously (Montefiori, 2009 ) (Supplemental Experimental Procedures and Table S1 ).
Formation of Protein Complexes, Crystallization, and Data Collection Antibody-gp120 complexes were formed by mixing deglycosylated HIV-1 gp120 with antibody Fab in a 1:1.2 molar ratio. The complexes were purified by size exclusion chromatography. Fractions with antibody-gp120 complexes were concentrated to $10 mg/ml for crystallization experiments. Crystallization conditions for all gp120-Fab complexes were obtained robotically and were manually optimized in hanging drops (Supplemental Experimental Procedures).
Structure Determination and Refinement
Structures were solved by molecular replacement with Phaser (McCoy et al., 2007) . Iterative model building and refinement procedures were carried out using Coot (Emsley and Cowtan, 2004) and Phenix (Adams et al., 2010) (Supplemental Experimental Procedures and Table S2 ).
Bioinformatics Analysis of Antibody Neutralization and 454 Sequencing Data
The neutralization fingerprints of antibodies were analyzed with procedures described previously . High-throughput B cell sequencing of donor samples, bioinformatics processing of sequencing data, and cross-donor phylogenetic analysis of antibody sequences were carried out with similar procedures as described (Wu et al., 2011; Zhu et al., 2012 ; Supplemental Experimental Procedures and Table S5 )
Structural Analysis
All antibody complexes were aligned over the outer domain of HIV-1 gp120 to gain a common reference frame for further comparison of the modes of recognition to the CD4-binding site. The BG505.664 SOSIP crystal structure (PDB ID: 4TVP) was used to analyze antibody recognition on the HIV-1 viral spike (Pancera et al., 2014; Supplemental Experimental Procedures) . 
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